In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Jung Won Shin

Senior Editor

Seoul, South Korea

Jung Won focuses on coverage of all aspects of news in the Korean pharma and biotech industry as well as for regulatory matters. She covers major pharma and biotech conferences in Korea as well as interviewing key opinion leaders. She also handles a regular Korean language podcast on Scrip/Pink Sheet stories. She has worked previously for Dow Jones Newswires, covering various industry sectors and the economy.

Latest From Jung Won Shin

Orange Grove CEO: Korean Opportunities A Priority In Global Expansion

US-based Orange Grove Bio inks first international partnerships with Korean universities, laying the foundation for its planned role as a bridge between the biotech industries in the two countries and to identify, develop and commercialize novel assets emerging from academic research.

South Korea United States

Asia Deal Watch: Avenue Takes On AnnJi’s Spinal And Bulbar Muscular Atrophy Candidate

Plus deals involving Ono/PeptiDream, Onconic/Livzon, Teijin/Novartis, Eisai/Biogen, Abbisko/Allist, Daewoong/M8, GC Biopharma/Catalyst and KYM Biosciences/AstraZeneca.

Deal Watch Business Strategies

Dong-A ST Faces New Wave Of Change As It Challenges Norms

Dong-A ST’s president of R&D Jae-Hong Park talks to Scrip about the changes needed in the domestic pharma sector and wider industry if Korean biopharma firms are to step up to global levels.

South Korea Business Strategies

How KIMCo Is Orchestrating Korean Pharma Collaborations

KIMCo CEO Kevin Kyunghwa Huh talks about the consortium's efforts to become a platform of collaboration for Korean pharmas, including plans for the latest joint investment project as well as how the domestic industry is evolving in terms of globalization and open innovation.

South Korea Deals

Korea’s Biopharma Regulatory Reform Push To Focus On Innovation, Streamlining

South Korea is aiming to implement a broad range of regulatory reform steps to better compete with global rivals and speed up patient access to novel therapies.

South Korea Digital Health

Korean CDMO Industry Entering A Renaissance Or Growing Too Fast?

The Korean contract development and manufacturing industry is rapidly growing with more established firms and newcomers set to sharply expand capacities and diversify portfolios, but competition to secure relevant workforce in the country is also getting fiercer.

South Korea Manufacturing
See All
UsernamePublicRestriction

Register